Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
12:25pm, Friday, 25'th Oct 2024
Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week pri
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
06:50am, Wednesday, 16'th Oct 2024
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat here
HAE or BSX: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 14'th Oct 2024
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to valu
Robust Plasma Sales, New Innovations Aid Haemonetics Stock
02:58pm, Tuesday, 08'th Oct 2024
HAE's hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024
04:05pm, Thursday, 03'rd Oct 2024
BOSTON , Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, Nov
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
06:50am, Thursday, 03'rd Oct 2024
ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat here
HAE vs. BSX: Which Stock Is the Better Value Option?
12:46pm, Friday, 27'th Sep 2024
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those
Here's Why You Should Add HAE Stock in Your Portfolio Now
09:51am, Thursday, 26'th Sep 2024
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
4 Medical Product Stocks to Buy From a Prospective Industry
09:11am, Tuesday, 24'th Sep 2024
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
HAE or BSX: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 11'th Sep 2024
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang f
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat her
After Plunging -15.88% in 4 Weeks, Here's Why the Trend Might Reverse for Haemonetics (HAE)
10:36am, Monday, 02'nd Sep 2024
Haemonetics (HAE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimate
